Last reviewed · How we verify

NCT05357885

Quantitative COVID-19 SARS-CoV-2 Antibody Pre and Post Cardiopulmonary Bypass

Completed Last updated 3 May 2022
What this trial tests

trial testing SARS-CoV-2 Antibody test in Laboratory Assessment SARS-CoV-2 Antibody Levels Before and After Surgery for Patients Requiring Cardiopulmonary Bypass in 60 participants. Completed in 17 March 2022.

Timeline
17 November 2021
Primary endpoint
17 March 2022
17 March 2022

Quick facts

Lead sponsorThomas Jefferson University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment60
Start date17 November 2021
Primary completion17 March 2022
Estimated completion17 March 2022
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Thomas Jefferson University

Who can join

18 and older, any sex, with Laboratory Assessment SARS-CoV-2 Antibody Levels Before and After Surgery for Patients Requiring Cardiopulmonary Bypass. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is designed to compare the levels of SARS-CoV-2 antibody prior to cardiopulmonary bypass and after cardiopulmonary bypass (CPB).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Thomas Jefferson University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05357885.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing